A new issue brief by America's Health Insurance Plans explores the recent trends in the specialty drug market and recommends policy solutions to promote high-value, high-quality care.
Despite accounting for just 1% of prescriptions written in 2014, specialty drugs represented nearly one-third of the total prescription drug spending. With specialty drugs representing an increasing share of the US prescription drug spend, addressing the cost trend is becoming critical to ensure affordability for businesses and consumers.
A new specialty drugs issue brief by America’s Health Insurance Plans (AHIP) explored the recent trends in the market and recommended policy solutions to promote high-value, high-quality care.
The unsustainable growth of spending on specialty drugs is the result of many factors, but mostly legal and regulatory treatment of specialty therapies is to be blamed, according to the issue brief.
AHIP explains that one of the biggest issues is the lengthy exclusivity period—12 years for brand-name biologic drugs—granted to specialty drugs.
“Granting lengthy exclusivity periods to specialty drugs removes the economic benefits of price competition, resulting in higher prices relative to what they would be in a perfectly competitive market,” according to the brief.
In addition, there is evidence of manufacturers gaming the system to prolong the exclusivity period even longer through a number of schemes including: “evergreening,” where manufacturers make minor changes to a drug’s chemical composition or delivery mechanism to extend the patent; and “product hopping,” when the company withdraws a drug from the market and introduces a new version with minor changes.
The AHIP brief recommended a number of policy options that would promote high-quality, cost-effective drug coverage, including:
“These recommendations represent actionable steps that could be implemented to ensure the efficient and effective use of these high-cost treatments while—at the same time—promoting continued medical advances and innovations that offer promise and benefit patients and consumers,” the brief concluded.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Homelessness Compounds Hospital Stay Challenges: Study Reveals Prolonged Discharge Struggles
March 28th 2024In this investigation, outcomes of interest were morbidity rate and length of hospital stay or a traumatic injury among a homeless population, and whether age and/or injury severity had an influence on that relationship—with implications for improving the discharge process for these patients.
Read More
FDA Approves Vadadustat for Anemia in Patients With CKD Undergoing Dialysis
March 28th 2024The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment option as anemia is common in these patients and can significantly impact their quality of life.
Read More